Harvard Business School March 15, 2021
Amitabh Chandra, Evan Flack, and Ziad Obermeyer

Small increases in cost cause patients to reduce their use of drugs with major benefits, ultimately causing their death. Since patient cost-sharing introduces large and deadly distortions into the cost-benefit calculus, payers should evaluate the merits of policies in light of their impact on health, not just on health care costs.
Author Abstract

We use the design of Medicare’s prescription drug benefit program to demonstrate three facts about the health consequences of cost-sharing. First, we show that small increases in out-of-pocket prices (11.0 percentage points (p.p.) change in coinsurance, or $10.40 per drug) causes a 22.6% drop in total drug consumption ($61.20), and a 32.7% increase in monthly mortality (0.048 p.p.). Second, we trace this...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Healthcare System, Insurance, Patient / Consumer, Pharma / Biotech, Pricing / Spending, Provider
Mark Cuban's drug company teams up with platform to bring patients pricing info
California is Capping Health Care Cost Increases - Starting at 3.5% in 2025
Senator asks for investigation on use of algorithms in healthcare pricing
The Cost of Medical Care, Long-Term Care, and Prescription Drugs Top Older Americans’ Health-Related Concerns – With Social Security and Medicare Top of Mind
Opinion: The world is relying on the United States to get value-based drug pricing right

Share This Article